Nagendran Sukumar 4

What Happened

• Nagendran Sukumar, a director of Solid Biosciences (SLDB), received a derivative award on June 10, 2026: an option covering 77,500 shares reported at $0.00 (no cash paid at grant). This is a compensation/award transaction, not an open-market purchase or sale.

Key Details

• Transaction date: June 10, 2026; Form 4 filed June 11, 2026 (filed the next day; appears timely under usual Form 4 rules).
• Transaction type: Grant / Award (derivative option) — 77,500 shares reported at $0.00.
• Exercise price / per-share strike: Not specified in the provided filing details.
• Shares owned after transaction: Not specified in the provided filing details.
• Footnote: The option vests in full on the earlier of the one-year anniversary of the grant date and immediately prior to the issuer's next annual meeting following the grant; it also accelerates to 100% vesting upon certain change-in-control events.

Context

• This is a typical equity compensation grant to a director (signals retention/compensation, not an immediate cash investment by the insider).
• Because it is an unexercised option award, no shares were purchased or sold at the time of grant; any future purchase or sale would be separate and reported when executed.